Science News · Wetenschap

Migraine Prevention Guidelines Updated with New Targeted Therapies

New guidelines from the American Academy of Neurology and American Headache Society, published August 31, 2026, incorporate recent advancements in migraine prevention, including drugs targeting calcitonin gene-related peptide (CGRP). These updated recommendations aim to help clinicians prescribe preventive treatments more confidently.

For the first time in 14 years, doctors have updated guidelines for preventing migraine attacks. The new recommendations incorporate evidence on treatments that weren’t available when the guidelines were last updated, such as CGRP-targeted drugs like Aimovig and Ajovy, which have shown significant success for some patients. These newer drugs, available in various forms, are now considered first-line treatment options by the American Headache Society. Older treatments like beta-blockers and certain antiseizure medications remain options for patients preferring a longer track record or lower cost.

The updated guidelines recommend preventive treatment for approximately 8 million U.S. adults experiencing frequent migraine attacks or whose migraines significantly interfere with daily life, a criterion not explicitly detailed in previous guidelines. The shift towards disease-specific, mechanism-based treatments like CGRP inhibitors represents a paradigm change, offering higher efficacy and better tolerability compared to older, less targeted therapies.

Choosing the right preventive treatment involves considering patient preference for medication delivery (e.g., pills vs. injections) and co-existing conditions (comorbidities) such as anxiety, depression, or hypertension, as some medications can address both migraine and these other health issues. Despite advances in targeted therapies, predicting which specific treatment will work best for an individual remains challenging due to the complex genetic and clinical heterogeneity of migraine.

Researchers are exploring other mediators of migraine beyond CGRP, as some patients do not respond to CGRP-targeted drugs. This suggests that different mechanisms may be involved in migraine pathophysiology for different individuals. Investigations into novel targets, such as pituitary adenylate cyclase-activating polypeptide (PACAP), are ongoing to develop more personalized treatment approaches.

AI-samenvatting op basis van de bron.